论文部分内容阅读
目的:探讨甘精胰岛素联用格列齐特缓释片治疗磺脲类药物继发性失效的2型糖尿病患者的疗效及安全性。方法:56例口服降糖药血糖控制不理想的2型糖尿病患者随机分为甘精胰岛素治疗组(IG组)和中性鱼精蛋白锌胰岛素(NPH)组,予睡前皮下注射胰岛素联合口服格列齐特缓释片治疗12周,比较两组疗效及安全性。结果:治疗后两组空腹血糖(FPG)、餐后2h血浆血糖(2hPG)、糖化血红蛋白(HbAlc)均明显下降,但IG组低血糖事件明显少于NPH组(P<0.01)。结论:甘精胰岛素联用格列齐特缓释片治疗2型糖尿病的方案安全有效,简便易行,能减少低血糖事件的发生。
Objective: To investigate the efficacy and safety of glargine combined with gliclazide in the treatment of type 2 diabetic patients with secondary failure of sulfonylureas. Methods: Fifty-six patients with type 2 diabetes who did not control the blood sugar of oral hypoglycemic agents were randomly divided into insulin glargine group (IG group) and neutral protamine zinc insulin group (NPH group) Gliclazide sustained-release tablets for 12 weeks, the two groups were compared efficacy and safety. Results: Fasting plasma glucose (FPG), postprandial 2h plasma glucose (2hPG) and HbAlc in both groups were significantly decreased after treatment, but the incidence of hypoglycemia in IG group was significantly less than that in NPH group (P <0.01). Conclusion: Glargine and Gliclazide Sustained-release Tablets are safe and effective in the treatment of type 2 diabetes mellitus, which is simple, easy and can reduce the incidence of hypoglycemic events.